Helsinn Boosts Oncology Portfolio with BridgeBio’s Infigratinib

By Michelle Liu

Pharma Deals Review: Vol 2021 Issue 4 (Table of Contents)

Published: 9 Apr-2021

DOI: 10.3833/pdr.v2021.i4.2604     ISSN: 1756-7874

Section: Research & Development



Helsinn Group has agreed to partner with QED Therapeutics, an affiliate of BridgeBio Pharma, to develop and commercialise the latter’s fibroblast growth factor receptors 1-3 (FGFR1-3) inhibitor, infigratinib, in oncology and all other indications except for skeletal dysplasias...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details